← Leaderboards
Zachary S. Clayton
University Of Colorado
$936,950
Attributed
$936,950
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $249K · FY2020–25$250K$187.5K$125K$62.5K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$936,950 · 3
By mechanism
R00$497,999 · 1
K99$349,920 · 1
F32$89,031 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado
Same institution · by research overlap
- Douglas R Seals$39,040,406
- Alex J Barker$2,258,100
- Matthew J Rossman$1,391,900
- Kristen Lynn Nowak$5,825,106
- Vienna E Brunt$1,185,080
Others in their field
Other Emerging Leaders on “Future”
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- John E West · University Of Texas At Austin$128,483,161
- Beth Baseler · Leidos Biomedical Research, Inc.$117,364,154
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- April Brinkoetter · Hungry Heart Media, Inc.$57,302,265
Research focus
FutureLaboratoriesEndotheliumFundingImpairmentInternationalDoxorubicinEndothelial CellsCardiovascular Disorder RiskExtramural ActivitiesCarotid ArteriesArteriesAtherosclerosisInsightCessation Of LifeChemotherapyBiological AvailabilityCardiovascular DiseasesAntioxidantsBlood VesselsCardiovascular PhysiologyEventCardiovascular SystemLearning
Grant awards (6)
Translational studies of cellular senescence as a regulator of doxorubicin-mediated arterial dysfunction$248,999
R00 · FY2025 · HL · contact PI
Translational studies of cellular senescence as a regulator of doxorubicin-mediated arterial dysfunction$249,000
R00 · FY2024 · HL · contact PI
Translational studies of cellular senescence as a regulator of doxorubicin-mediated arterial dysfunction$174,960
K99 · FY2023 · HL · contact PI
Translational studies of cellular senescence as a regulator of doxorubicin-mediated arterial dysfunction$174,960
K99 · FY2022 · HL · contact PI
Mitochondrial oxidative stress: a target for treatment of doxorubicin-associated vascular endothelial dysfunction$24,105
F32 · FY2021 · HL · contact PI
Mitochondrial oxidative stress: a target for treatment of doxorubicin-associated vascular endothelial dysfunction$64,926
F32 · FY2020 · HL · contact PI